神経変性治療薬の世界市場

神経変性治療薬の世界市場は2030年までに649億米ドルに達する

2024年に437億米ドルと推定される神経変性治療薬の世界市場は、分析期間2024-2030年にCAGR 6.8%で成長し、2030年には649億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるドパミンアゴニストは、CAGR 8.3%を記録し、分析期間終了時には257億米ドルに達すると予想されます。脱炭酸酵素阻害剤セグメントの成長率は、分析期間中CAGR 7.6%と推定されます。

米国市場は119億米ドルと推定、中国はCAGR10.9%で成長予測

米国の神経変性治療薬市場は、2024年には119億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに137億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.3％と6.7％と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界の神経変性治療薬市場- 主要動向と促進要因のまとめ

神経変性疾患の治療薬開発が臨床的・商業的に再び注目される理由とは？

アルツハイマー病、パーキンソン病、筋萎縮性側索硬化症（ALS）、ハンチントン病、多系統萎縮症などの神経変性疾患は、世界の医療における最も緊急かつ複雑な課題の一つです。これらの疾患は進行性の神経細胞劣化を伴い、その結果、認知、運動、行動の障害を引き起こし、時間の経過とともに悪化するが、ほとんど治らないです。世界の高齢化に伴い、これらの疾患の発症率は劇的に増加しており、ヘルスケア・システムと介護者に多大な負担を強いています。その結果、神経変性治療薬市場は、製薬会社、バイオテクノロジー企業、公衆衛生機関からの関心が急増しています。

歴史的に、神経変性疾患の治療薬パイプラインは、高い離脱率、限られた有効性、安全性の懸念に悩まされてきました。しかし、遺伝学、タンパク質のミスフォールディング研究、神経免疫学における飛躍的な進歩により、現在では対症療法ではなく、根本的な病態生理学をターゲットとする疾患修飾療法（DMT）の開発が進められています。政府の優遇措置、ファスト・トラック指定、官民の研究イニシアティブにより、技術革新に有利なエコシステムが構築されつつあります。神経変性の社会的・経済的負担が増大する中、医薬品開発者は、その医学的重要性だけでなく、膨大なアンメット市場の可能性からも、この治療領域を優先しています。

疾患修飾アプローチと新規メカニズムは、神経変性治療薬の将来をどのように形作るのか？

最近の疾患生物学の動向は、薬剤開発の焦点を対症療法から疾患修飾的介入へとシフトさせています。アルツハイマー病では、βアミロイド（アデュカヌマブ、レカネマブなど）やタウ蛋白を標的とするモノクローナル抗体が臨床評価中であり、条件付き承認を受けています。パーキンソン病では、αシヌクレインを標的とする免疫療法、LRRK2阻害剤、ドーパミン受容体作動薬が、ドーパミン作動性神経細胞の減少を遅らせるために研究されています。遺伝子治療、RNA標的薬（アンチセンス・オリゴヌクレオチドのような）、神経栄養因子モジュレーターもまた、複数の病態で試験中です。

神経炎症、ミトコンドリア機能障害、タンパク質凝集、酸化ストレスを標的とする低分子は、治療メカニズムの幅を広げています。さらに、腫瘍学や免疫学から再利用された薬剤が、神経変性疾患における後期臨床試験に入りつつあります。バイオマーカー主導型の患者選択、デジタルフェノタイピング、髄液バイオマーカー（髄液ニューロフィラメント軽鎖など）の使用は、臨床試験の効率と治療の個別化を向上させています。これらの技術革新は、緩和から疾患経過の潜在的変化への重要な移行を示すものであり、治療への期待や規制経路に新たな先例を示すものです。

神経変性治療薬の需要を牽引している患者セグメントと世界地域は？

神経変性治療薬の主な患者層は高齢者、特にアルツハイマー病やパーキンソン病で最も罹患しているコホートを代表する65歳以上です。早期発症者や遺伝的素因を持つ人々もまた、ゲノムスクリーニングによって特定され、より詳細にモニターされるようになっており、より早期の介入戦略を可能にしています。軽度認知障害（MCI）や前駆期パーキンソン病の診断が増加していることから、治療の余地が拡大し、早期段階の治療薬に対する需要が高まっています。

地理的には、北米が神経変性治療薬市場を独占しているが、これは強固な研究開発インフラ、高い診断普及率、新規治療薬の早期導入によるものです。欧州は、希少な神経変性疾患に対する強力な規制支援と協調的な認知症ケアイニシアチブを背景に、これに続いています。アジア太平洋は成長フロンティアとして台頭してきており、特に日本と中国では急速に高齢化が進み、神経学的研究への投資が増加しているため、需要が加速しています。世界の認知度向上キャンペーン、介護者支援プログラム、遠隔診療の拡大により、特に資源不足の地域ではアクセスとアドヒアランスが促進されています。

神経変性治療薬市場の長期的成長と革新の原動力は？

神経変性治療薬市場の成長の原動力は、人口動向、神経科学の進歩、脳の健康に対する公的・民間投資の増加です。高齢化社会は、早期介入戦略や長期的な疾病管理ソリューションへの資金提供を促しています。規制機関は、ハイリスク・ハイフェイラー領域における治療イノベーションを奨励するため、早期審査パスウェイ、条件付き承認、希少疾病用医薬品のインセンティブを提供しています。一方、ベンチャーキャピタルや大手製薬会社との提携により、新規作用機序を持つ神経領域の新興企業に資金が流入しています。

デジタルバイオマーカー、AIによる創薬支援、患者層別化ツールは、臨床試験の結果を改善し、精密な神経治療を可能にしています。リアルワールドエビデンス（RWE）と市販後調査は、規制当局の決定をサポートし、償還戦略に情報を提供するために使用されています。神経変性の社会的被害が増大するにつれ、治療アプローチは併用レジメン、神経回復戦略、非侵襲的神経調節などへと拡大しています。これらの要因を総合すると、神経変性治療薬は今後数十年間、イノベーション、投資、ヘルスケア変革の最前線に位置し続けることが確実です。

セグメント

薬剤クラス（ドパミン作動薬、脱炭酸酵素阻害薬、コリンエステラーゼ阻害薬、免疫調節薬、その他の薬剤クラス）、適応症（パーキンソン病、アルツハイマー病、多発性硬化症、その他の適応症）、流通チャネル（病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局）

調査対象企業の例（全34件）

• AbbVie Inc.
• AC Immune SA
• Acorda Therapeutics, Inc.
• Alector, Inc.
• Alnylam Pharmaceuticals, Inc.
• Amylyx Pharmaceuticals, Inc.
• Biogen Inc.
• Boehringer Ingelheim GmbH
• CervoMed Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genentech, Inc.
• H. Lundbeck A/S
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Neurodegenerative Drugs Market to Reach US$64.9 Billion by 2030

The global market for Neurodegenerative Drugs estimated at US$43.7 Billion in the year 2024, is expected to reach US$64.9 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Dopamine Agonist, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.7 Billion by the end of the analysis period. Growth in the Decarboxylase Inhibitors segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.9 Billion While China is Forecast to Grow at 10.9% CAGR

The Neurodegenerative Drugs market in the U.S. is estimated at US$11.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$13.7 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Neurodegenerative Drugs Market - Key Trends & Drivers Summarized

Why Is Drug Development for Neurodegenerative Diseases Receiving Renewed Clinical and Commercial Focus?

Neurodegenerative diseases-such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple system atrophy-represent one of the most urgent and complex challenges in global medicine. These disorders involve progressive neuronal degradation, resulting in cognitive, motor, and behavioral impairments that worsen over time and remain largely incurable. As aging populations rise globally, the incidence of these conditions is increasing dramatically, placing immense pressure on healthcare systems and caregivers. Consequently, the market for neurodegenerative drugs is witnessing a surge in interest from pharmaceutical companies, biotech firms, and public health institutions.

Historically, the drug pipeline for neurodegenerative disorders has been plagued by high attrition rates, limited efficacy, and safety concerns. However, breakthroughs in genetics, protein misfolding research, and neuroimmunology are now driving the development of disease-modifying therapies (DMTs) that target underlying pathophysiology rather than just symptomatic relief. Government incentives, fast-track designations, and public-private research initiatives are creating a favorable ecosystem for innovation. As the societal and economic burden of neurodegeneration escalates, drug developers are prioritizing this therapeutic area not only for its medical importance but also for its massive unmet market potential.

How Are Disease-Modifying Approaches and Novel Mechanisms Shaping the Future of Neurodegenerative Drug Therapies?

Recent advances in disease biology have shifted the focus of drug development from symptomatic management to disease-modifying interventions. For Alzheimer’s, monoclonal antibodies targeting beta-amyloid (e.g., aducanumab, lecanemab) and tau proteins are under clinical evaluation and conditional approvals. In Parkinson’s disease, alpha-synuclein-targeting immunotherapies, LRRK2 inhibitors, and dopamine receptor agonists are being studied to slow dopaminergic neuronal loss. Gene therapies, RNA-targeting drugs (like antisense oligonucleotides), and neurotrophic factor modulators are also being trialed across multiple conditions.

Small molecules targeting neuroinflammation, mitochondrial dysfunction, protein aggregation, and oxidative stress are expanding the scope of therapeutic mechanisms. Additionally, repurposed agents from oncology and immunology are entering late-stage trials in neurodegenerative settings. Biomarker-driven patient selection, digital phenotyping, and the use of fluid biomarkers (such as CSF neurofilament light chain) are improving trial efficiency and therapeutic personalization. These innovations mark a critical transition from palliation to potential alteration of disease trajectory, setting a new precedent for treatment expectations and regulatory pathways.

Which Patient Segments and Global Regions Are Driving Demand for Neurodegenerative Drugs?

The primary patient demographics for neurodegenerative drugs are older adults, especially those over 65, who represent the most affected cohort for Alzheimer’s and Parkinson’s. Early-onset and genetically predisposed populations are also being identified and monitored more closely through genomic screening, enabling earlier intervention strategies. The increasing diagnosis of mild cognitive impairment (MCI) and prodromal Parkinson’s is expanding the treatment window and driving demand for early-stage therapeutics.

Geographically, North America dominates the neurodegenerative drug market due to robust R&D infrastructure, high diagnostic penetration, and early adoption of novel therapeutics. Europe follows with strong regulatory support for rare neurodegenerative conditions and coordinated dementia care initiatives. Asia-Pacific is emerging as a growth frontier, particularly in Japan and China, where rapidly aging populations and increasing investment in neurological research are accelerating demand. Global awareness campaigns, caregiver support programs, and telemedicine expansion are facilitating access and adherence, especially in under-resourced regions.

What Is Fueling Long-Term Growth and Innovation in the Neurodegenerative Drugs Market?

The growth in the neurodegenerative drugs market is driven by demographic trends, advances in neuroscience, and increasing public and private investment in brain health. Aging societies are catalyzing funding for early intervention strategies and long-term disease management solutions. Regulatory bodies are offering accelerated review pathways, conditional approvals, and orphan drug incentives to encourage therapeutic innovation in high-risk, high-failure domains. Meanwhile, venture capital and big pharma partnerships are funneling resources into neurology startups with novel mechanisms of action.

Digital biomarkers, AI-assisted drug discovery, and patient stratification tools are improving trial outcomes and enabling precision neurotherapeutics. Real-world evidence (RWE) and post-market surveillance are being used to support regulatory decisions and inform reimbursement strategies. As the societal toll of neurodegeneration intensifies, therapeutic approaches are expanding to include combination regimens, neurorestorative strategies, and non-invasive neuromodulation. Collectively, these factors ensure that neurodegenerative drugs will remain at the forefront of innovation, investment, and healthcare transformation in the coming decades.

SCOPE OF STUDY:

The report analyzes the Neurodegenerative Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators, Other Drug Classes); Indication (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Other Indications); Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores & Retail Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• AC Immune SA
• Acorda Therapeutics, Inc.
• Alector, Inc.
• Alnylam Pharmaceuticals, Inc.
• Amylyx Pharmaceuticals, Inc.
• Biogen Inc.
• Boehringer Ingelheim GmbH
• CervoMed Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genentech, Inc.
• H. Lundbeck A/S
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Neurodegenerative Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Alzheimer's, Parkinson's, and ALS Propels Demand for Neurodegenerative Therapies
  • Expansion of Aging Global Population Strengthens Business Case for Long-Term CNS Treatments
  • Advancements in Amyloid and Tau-Targeting Drug Development Accelerate Clinical Trial Activity
  • Surge in Orphan Drug Approvals Throws the Spotlight on Rare Neurological Disorders
  • Increased Investment in CNS Drug Discovery Enhances Innovation in Neuroprotective Agents
  • Adoption of Biomarker-Guided Clinical Trials Supports Early Detection and Patient Stratification
  • Integration of AI in Neurodegenerative Drug Research Enables Faster Target Identification
  • Improved Understanding of Disease Pathophysiology Spurs Development of Disease-Modifying Therapies
  • Growth in Neurorehabilitation Support Programs Enhances Market Adoption Synergies
  • Rising Use of mRNA and Gene Therapies Expands Future Treatment Modalities
  • Emergence of Multimodal Drug Formulations Strengthens Combination Therapy Frameworks
  • Regulatory Incentives for Breakthrough Therapies Accelerate Pipeline Advancements
  • Challenges in CNS Drug Delivery and BBB Penetration Drive Nanotechnology-Based Innovation
  • Increased Focus on Real-World Evidence Collection Supports Post-Marketing Surveillance
  • Expansion of Collaborative Research Between Academia and Biopharma Enhances Portfolio Diversity
  • Growing Inclusion of Patient-Reported Outcomes Enhances Therapy Value Demonstration
  • Availability of Companion Diagnostics Boosts Personalization of Neurodegenerative Treatments
  • Societal and Economic Burden of Dementia Drives Policy-Level Attention and Funding
  • Uneven Access to Advanced Therapies Across Geographies Creates Global Disparities
  • Rise in Caregiver Support Ecosystems Supports Holistic Drug Adoption Pathways
  • Expansion of Digital Health Tools and Wearables Drives Remote Monitoring of Treatment Response
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neurodegenerative Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Dopamine Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Dopamine Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Dopamine Agonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Decarboxylase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Decarboxylase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Decarboxylase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Parkinson's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• JAPAN
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• CHINA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• EUROPE
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• FRANCE
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• GERMANY
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• INDIA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Neurodegenerative Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Neurodegenerative Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030
• AFRICA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Neurodegenerative Drugs by Drug Class - Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Neurodegenerative Drugs by Drug Class - Percentage Breakdown of Value Sales for Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Neurodegenerative Drugs by Distribution Channel - Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Neurodegenerative Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Neurodegenerative Drugs by Indication - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Neurodegenerative Drugs by Indication - Percentage Breakdown of Value Sales for Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION